Lumonus Raises $25 Mn Series B to Scale AI-Powered Oncology Workflows

The Series B funding will support the US go-to-market and clinical success teams, and is expected to advance its flagship products, Lumonus AI Physician and Lumonus AI Dosimetry, and further invest in clinical informatics capabilities.

Australian healthtech company Lumonus has announced the closing of a $25 million Series B financing round, led by Aviron Investment Management, with continued backing from Oncology Venture.

The new capital will be deployed to expand its global footprint, accelerate product development, and deepen clinical integrations in major oncology centers worldwide.

The startup is already operating in the United States, Australia, and Europe, where the AI platform has already been integrated into routine clinical care.

To date, the AI-powered platform has supported clinicians in consulting and prescribing more than 280,000 cancer treatments and has automated the creation of over 75,000 treatment plans.

Speaking about the new investment, Keith Hansen, Chief Executive Officer of Lumonus, said, "Scientific innovation in cancer treatment has advanced significantly, but the systems that support teams delivering the care have not kept pace. By combining AI-native architecture, a comprehensive end-to-end workflow approach, and a commitment to partnering with care teams to solve real-world pain points, we are reimagining oncology workflows. This investment allows us to expand our world-class team and support more health systems that are ready to embrace a better way."

Lumonus focuses on leveraging artificial intelligence to automate and optimise radiation oncology processes, including dosimetry and treatment-planning workflows.

Reportedly, the Series B funding will support the US go-to-market and clinical success teams, and is expected to advance its flagship products, Lumonus AI Physician and Lumonus AI Dosimetry, and further invest in clinical informatics capabilities.

The company also plans to strengthen its collaboration with health systems to harness real-world evidence, measure quality, improve operational performance, and deliver more personalised, data-driven care.

Commenting in this regard, Merrick Howes, Chairman of Lumonus.

"Our unique AI-native platform has already demonstrated its ability to improve clinical quality and operational efficiency. This new capital will allow us to accelerate both product innovation and expand our U.S. commercial footprint."

Stay tuned for more such updates on Digital Health News